Cargando…

Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Krebs von den Lungen-6 (KL-6) levels measured at baseline have been reported as a circulating biomarker useful for the detection, evaluation of severity and assessment of risk of the progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In this retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirai, Yuichiro, Fukue, Ryosuke, Kaneko, Yuko, Kuwana, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619247/
https://www.ncbi.nlm.nih.gov/pubmed/34829353
http://dx.doi.org/10.3390/diagnostics11112007
_version_ 1784604943828647936
author Shirai, Yuichiro
Fukue, Ryosuke
Kaneko, Yuko
Kuwana, Masataka
author_facet Shirai, Yuichiro
Fukue, Ryosuke
Kaneko, Yuko
Kuwana, Masataka
author_sort Shirai, Yuichiro
collection PubMed
description Krebs von den Lungen-6 (KL-6) levels measured at baseline have been reported as a circulating biomarker useful for the detection, evaluation of severity and assessment of risk of the progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In this retrospective study, longitudinal changes in serum KL-6 levels over 2 years were examined in 110 patients with SSc using prospectively collected cohort data. Serum KL-6 levels fluctuated in a significant proportion of the patients but remained stable in the remaining patients. A wide range of variability of longitudinal KL-6 levels was associated with the presence of ILD, diffuse cutaneous SSc, positive anti-topoisomerase I antibodies, negative anticentromere antibodies, increased ILD extent on high-resolution computed tomography, extensive disease, low pulmonary function parameters, high KL-6 levels at baseline and immunomodulatory treatment. Extensive disease was consistently identified as an independent factor associated with variability in KL-6 levels in different models of multiple regression analysis. We failed to demonstrate correlations between trends for KL-6 level changes during the 6 months after SSc diagnosis and ILD progression over 2 years in patients with SSc-ILD. Serum KL-6 levels fluctuate in SSc patients with ILD, especially in those with extensive disease, but the clinical utility of a serial KL-6 level measurement remains uncertain.
format Online
Article
Text
id pubmed-8619247
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86192472021-11-27 Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease Shirai, Yuichiro Fukue, Ryosuke Kaneko, Yuko Kuwana, Masataka Diagnostics (Basel) Article Krebs von den Lungen-6 (KL-6) levels measured at baseline have been reported as a circulating biomarker useful for the detection, evaluation of severity and assessment of risk of the progression of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). In this retrospective study, longitudinal changes in serum KL-6 levels over 2 years were examined in 110 patients with SSc using prospectively collected cohort data. Serum KL-6 levels fluctuated in a significant proportion of the patients but remained stable in the remaining patients. A wide range of variability of longitudinal KL-6 levels was associated with the presence of ILD, diffuse cutaneous SSc, positive anti-topoisomerase I antibodies, negative anticentromere antibodies, increased ILD extent on high-resolution computed tomography, extensive disease, low pulmonary function parameters, high KL-6 levels at baseline and immunomodulatory treatment. Extensive disease was consistently identified as an independent factor associated with variability in KL-6 levels in different models of multiple regression analysis. We failed to demonstrate correlations between trends for KL-6 level changes during the 6 months after SSc diagnosis and ILD progression over 2 years in patients with SSc-ILD. Serum KL-6 levels fluctuate in SSc patients with ILD, especially in those with extensive disease, but the clinical utility of a serial KL-6 level measurement remains uncertain. MDPI 2021-10-28 /pmc/articles/PMC8619247/ /pubmed/34829353 http://dx.doi.org/10.3390/diagnostics11112007 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shirai, Yuichiro
Fukue, Ryosuke
Kaneko, Yuko
Kuwana, Masataka
Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_full Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_fullStr Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_full_unstemmed Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_short Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease
title_sort clinical relevance of the serial measurement of krebs von den lungen-6 levels in patients with systemic sclerosis-associated interstitial lung disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619247/
https://www.ncbi.nlm.nih.gov/pubmed/34829353
http://dx.doi.org/10.3390/diagnostics11112007
work_keys_str_mv AT shiraiyuichiro clinicalrelevanceoftheserialmeasurementofkrebsvondenlungen6levelsinpatientswithsystemicsclerosisassociatedinterstitiallungdisease
AT fukueryosuke clinicalrelevanceoftheserialmeasurementofkrebsvondenlungen6levelsinpatientswithsystemicsclerosisassociatedinterstitiallungdisease
AT kanekoyuko clinicalrelevanceoftheserialmeasurementofkrebsvondenlungen6levelsinpatientswithsystemicsclerosisassociatedinterstitiallungdisease
AT kuwanamasataka clinicalrelevanceoftheserialmeasurementofkrebsvondenlungen6levelsinpatientswithsystemicsclerosisassociatedinterstitiallungdisease